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Abstract 
 
Excessive activation of the renin-angiotensin 
system (RAS) in diabetic cardiomyopathy (DCM) 
provokes a series of structural and functional 
abnormalities, and causes ventricular remodeling 
and heart failure in diabetes. (Pro)renin receptor 
(PRR) is a component of the RAS and has been 
reported to be up-regulated in some 
cardiovascular diseases. Furthermore, PRR 
blockade in some cardiovascular diseases, such 
as myocardial infarction and hypertension, has 
been demonstrated to reverse their pathogenesis. 
However, there have been few studies about the 
function of PRR in the pathogenesis of DCM. In 
this study, we hypothesized that PRR is involved 
in the pathogenesis of DCM and mediates 
myocardial injury in DCM. To explore the role 
of PRR in DCM, we evaluated the effects of 
PRR overexpression and knockdown on the 
DCM phenotype in vivo and in vitro. The results 
show that PRR overexpression exacerbates 
myocardial injury and the inflammatory 
response in rats with DCM. Conversely, PRR 
knockdown alleviates myocardial fibrosis, 
apoptosis, and the inflammatory response, 
reversing the cardiac dysfunction in rats with 
DCM. In cell experiments, PRR overexpression 
also up-regulated the protein expression of 
collagen I and fibronectin, aggravated the 
inflammatory response, and increased the 
production of reactive oxygen species (ROS), 
while PRR knockdown had the opposite effect. 
Thus, PRR mediates myocardial injury, 
apoptosis, and the inflammatory response, likely 
through a PRR/extracellular signal-regulated 
kinase/ROS pathway. 
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Introduction 
 
Diabetes is an important chronic metabolic 
disease that substantially affects health and 
lifespan. Diabetic cardiovascular complications 
are major causes of death in diabetes. Previous 
studies have shown that diabetes not only 
exacerbates cardiovascular diseases, including 
atherosclerosis and hypertension, but is itself 
responsible for cardiac injury (1). Diabetic 
cardiomyopathy is one of the most serious 
complications of diabetes and is characterized 
by a series of structural and functional 
abnormalities, including myocardial fibrosis, 
inflammation, cellular apoptosis, and ventricular 
remodeling (2). A previous study showed that 
treatment aimed at alleviating myocardial 
fibrosis, apoptosis, and inflammation is 
protective against cardiac pathology in DCM(3). 
Excessive activation of the renin-angiotensin 
system (RAS) is reported to be important in the 
pathogenesis of DCM. RAS activation can 
induce or exacerbate myocardial fibrosis, 
oxidative stress, inflammation, and other 
pathological changes. However, although 
angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers are widely used in 
clinical practice, they do not substantially 
reduce the morbidity and mortality associated 
with the cardiovascular complications of 
diabetes. Thus, it is necessary to identify 
potential new therapeutic targets, the use of 
which might be associated with more satisfactory 
outcomes (4,5). 
(Pro)renin receptor (PRR) is a member of the 
RAS that was recently discovered and is widely 
expressed in blood vessels, the heart, and kidneys. 
PRR is a single trans-membrane protein that 
binds both renin and prorenin, and has been 
implicated in a number of cardiovascular 
diseases (6,7). Binding of ligand to PRR leads to 
renin activation and non-proteolytic activation of 
prorenin, the formation of angiotensin II (AngII), 
and the activation of a variety of 
AngII-independent signal transduction pathways, 
such as the mitogen-activated protein kinase 
(MAPK) signaling pathway (8). This dual 
function has led to the identification of PRR as a 
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 4 
potentially efficient therapeutic target. Specific 
PRR inhibition has been demonstrated to be 
beneficial in a range of diseases, including 
hypertension and diabetic nephropathy (9,10). 
Although few studies have evaluated the effects 
of PRR blockade in DCM, one recent study 
found that PRR expression in the myocardium is 
high in a rat model of DCM (11). 
We hypothesized that PRR mediates myocardial 
injury, apoptosis, and inflammatory responses in 
DCM. To evaluate the respective effects of PRR 
overexpression and knockdown on myocardial 
injury, apoptosis, and inflammatory responses in 
DCM, we conducted experiments in Wistar rats 
and cardiac fibroblasts in vitro. We 
overexpressed or silenced PRR expression using 
adenoviruses (Ad-PRR and Ad-PRR-short 
hairpin RNA [shRNA], respectively) and 
established a potential mechanism for the role of 
PRR in DCM. 
 
Results 
 
The effects of PRR overexpression and 
knockdown on myocardial injury 
Firstly, the effects of PRR overexpression on 
myocardial injury were determined. 
Immunohistochemistry revealed that fibronectin 
protein expression was higher in Ad-PRR-treated 
rats than in the DCM control group or in the 
adenoviruses carried enhanced green fluorescent 
protein (Ad-EGFP) treated group (Fig. 1A–B, 
P<0.05). The expression of profilin showed a 
similar trend, with expression in the Ad-PRR 
group being significantly higher than that in the 
DCM and Ad-EGFP groups (Fig. 1C–D, 
P<0.05). 
Secondly, the effects of PRR knockdown on 
myocardial fibrosis were also evaluated. The 
protein expression of collagen I and fibronectin 
in the three groups was also evaluated using 
immunohistochemistry, showing that collagen I 
expression was significantly lower in the 
Ad-PRR-shRNA group than in the DCM or 
Ad-SC-shRNA group (Fig. 2A–B, P<0.01), and a 
similar trend for the expression of fibronectin 
(Fig. 2C–D, P<0.05). 
In addition, the extent of cellular apoptosis was 
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 5 
assessed using a terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) 
assay, which showed that the percentage of 
apoptotic cells in the Ad-PRR-shRNA group 
was much lower than that in the DCM and 
Ad-SC-shRNA groups (Fig. 2E–F, P<0.01). 
 
The effects of PRR overexpression and 
knockdown on myocardial inflammation 
Firstly, tumor necrosis factor (TNF)-α and 
interleukin (IL)-6 protein expression was also 
evaluated using immunohistochemistry after 
PRR overexpression, showing that both were 
significantly higher in the Ad-PRR group than in 
the DCM and Ad-EGFP groups (Fig. 1E–H, 
P<0.05). 
Secondly, after PRR knockdown in DCM, 
immunohistochemistry revealed that IL-1 protein 
expression in myocardium was significantly 
lower in the Ad-PRR-shRNA group than in the 
DCM and Ad-SC-shRNA groups (Fig. 2G, 
P<0.01). Furthermore, the protein expression of 
IL-6 showed the same pattern (Fig. 2H, P<0.05). 
 
The effects of PRR overexpression and 
knockdown on superoxide dismutase and 
NADPH oxidase activities, and 
malondialdehyde content 
Superoxide dismutase (SOD) activity and 
malondialdehyde (MDA) content were measured 
after PRR overexpression. SOD activity in the 
Ad-PRR group was lower than in the DCM and 
Ad-EGFP groups (Fig. 1I, P<0.05), whereas the 
MDA content in the Ad-PRR group was higher 
than in the DCM and Ad-EGFP groups (Fig. 1J, 
P<0.05). In addition, NADPH oxidase activity 
was higher in the Ad-PRR group than in the 
DCM and Ad-EGFP groups (Fig. 1K, P<0.05). 
After PRR knockdown, SOD content in the 
Ad-PRR-shRNA group was higher than in the 
DCM and Ad-SC-shRNA groups (Fig. 3A, 
P<0.05). By contrast, compared with the DCM 
and Ad-SC-shRNA groups, the MDA content in 
the Ad-PRR-shRNA group was lower (Fig. 3B, 
P<0.05). Furthermore, NADPH oxidase activity 
was significantly lower in the Ad-PRR-shRNA 
group than in the DCM and Ad-SC-shRNA 
groups (Fig. 3C, P<0.01). 
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Effect of PRR silencing on cardiac function 
At the end of the study period, cardiac function 
was assessed in the Ad-PRR-shRNA, 
Ad-SC-shRNA, and DCM groups using 
echocardiography. This showed that the left 
ventricular ejection fraction (LVEF) was higher 
in the Ad-PRR-shRNA group than in the DCM 
and Ad-SC-shRNA groups (Fig. 3D, P<0.05). 
Both the left ventricular end-diastolic diameter 
(LVEDD) and the left ventricular end-systolic 
diameter (LVESD) were lower in the 
Ad-PRR-shRNA group than in the DCM and 
Ad-SC-shRNA groups (Fig. 3E–F, P<0.05). With 
regard to diastolic function, the ratio of flow 
Doppler E wave to A wave amplitude (E/A ratio) 
was much higher in the Ad-PRR-shRNA group 
than in the DCM and Ad-SC-shRNA groups (Fig. 
3G, P<0.01). 
 
Effects of PRR overexpression or silencing on 
ROS production and activation of the 
extracellular signal-regulated kinase pathway 
in vitro 
In the first instance, the degree of PRR protein 
overexpression in the cardiac fibroblasts was 
determined using western blotting, which 
showed that PRR protein expression was 
significantly higher in Ad-PRR-treated cells than 
in Ad-EGFP-treated or high glucose-treated cells 
(Figure 4A–B, P<0.01). However, the addition 
of the extracellular signal-regulated kinase (ERK) 
inhibitor PD98059 did not affect PRR protein 
expression. 
The effects of PRR overexpression on cardiac 
fibroblasts were also assessed. Western blotting 
showed that ERK phosphorylation was lower in 
Ad-PRR+PD98059-treated cells than in 
Ad-PRR-infected cells (Figure 4C–D, P<0.05). 
Dihydroethidium (DHE) assay showed that ROS 
production was higher in Ad-PRR-infected cells 
than in high glucose-treated or 
Ad-EGFP-infected cells, but lower in 
Ad-PRR+PD98059-treated cells than in 
Ad-PRR-infected cells (Figure 4E–F, P<0.05). 
We next measured PRR protein expression in 
Ad-PRR-shRNA-infected cells, and found that it 
was much lower than in high glucose-treated or 
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Ad-SC-shRNA-infected cells (Fig. 6A–B, 
P<0.05). In these cardiac fibroblasts, western 
blotting showed that ERK phosphorylation was 
lower in Ad-PRR-shRNA-infected cells than in 
high glucose-treated or Ad-SC-shRNA-infected 
cells (Figure 6C–D, P<0.05). DHE assay showed 
that ROS production was lower in 
Ad-PRR-shRNA-infected cells than in high 
glucose-treated or Ad-SC-shRNA-infected cells 
(Figure 6E–F, P<0.05). 
 
The effects of PRR overexpression and 
silencing on collagen I, fibronectin, IL-1, and 
IL-6 protein expression in vitro 
Collagen I and fibronectin gene and protein 
expression was measured using PCR and ELISA, 
respectively, in the cardiac fibroblasts. This 
showed that the expression of both genes at the 
mRNA and protein levels was higher in 
Ad-PRR-infected cells than in high 
glucose-treated or Ad-EGFP-infected cells, but 
lower in Ad-PRR+PD98059-treated cells (Figure 
5A–D, P<0.05). 
IL-1 and IL-6 expression was also measured 
using PCR and ELISA, which showed that both 
were expressed at lower levels in 
Ad-PRR+PD98059-treated cells than in 
Ad-PRR-infected cells at both the mRNA and 
protein levels (Figure 5E–H, P<0.05). 
Next, the effects of PRR knockdown on the 
protein expression of collagen I and fibronectin 
were measured. The ELISA results showed that 
the protein expression of collagen I and 
fibronectin was lower in 
Ad-PRR-shRNA-infected cells than in high 
glucose-treated or Ad-SC-shRNA-infected cells 
(Figure 6G–H, P<0.05). The same pattern of 
protein expression was also identified for IL-1 
and IL-6 using ELISA (Figure 6I–J, P<0.05). 
 
Discussion 
 
In this study, we have shown that PRR 
overexpression exacerbates myocardial injury, 
increases the inflammatory response, and 
increases oxidative stress in an animal model of 
DCM. By contrast, knockdown of PRR protein 
expression using RNA interference ameliorates 
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 8 
fibrosis, the inflammatory response, apoptosis, 
and defects in cardiac function in rats with 
DCM. In cardiac fibroblasts in vitro, we showed 
that PRR overexpression increases the 
production of ROS, activates the ERK pathway, 
and further increases the expression of collagen 
I, fibronectin, IL-1, and IL-6, both at the mRNA 
and protein levels. However, treatment with the 
ERK inhibitor PD98059 ameliorates the adverse 
gene expression profile resulting from PRR 
overexpression. In addition, PRR knockdown 
prevented the effects of high glucose-induced 
PRR up-regulation. Taken together, our findings 
indicate that PRR mediates myocardial injury, 
apoptosis, and the inflammatory response in 
DCM via a PRR/ERK/ROS pathway. 
Diabetic cardiomyopathy (DCM) is one of most 
serious cardiovascular complications of diabetes. 
It is characterized by several myocardial 
structural and functional abnormalities (1). The 
key components of the pathogenesis of DCM are 
myocardial fibrosis, left ventricular remodeling, 
and cardiac dysfunction (2). An important 
pathological feature of DCM is the 
accumulation of extracellular matrix (ECM) 
proteins, and a previous study demonstrated that 
the accumulation of ECM is induced by 
hyperglycemia (12). Singh et al. found that both 
intracellular and extracellular AngII contribute 
to the greater fibrosis mediated by cardiac 
fibroblasts in a high-glucose environment(12). 
Related studies have found that the binding of 
renin or prorenin to PRR leads to renin 
activation and non-proteolytic activation of 
prorenin, which induced further AngII synthesis 
and the activation of a variety of 
AngII-independent signal transduction pathways, 
which promote myocardial fibrosis. A recent 
clinical study showed that serum soluble 
(pro)renin receptor concentration reflects the 
severity of heart failure (13). Thus, lower PRR 
expression in disease models could reverse the 
pathogenesis of such diseases(14). The multiple 
functionality of PRR has led to it being thought 
of as a potentially novel and efficient therapeutic 
target for certain cardiac diseases. The present 
study has shown that PRR knockdown improves 
cardiac function, assessed using 
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 9 
echocardiography in rats with DCM, which 
suggests that PRR down-regulation might be 
able to ameliorate the cardiac dysfunction 
associated with DCM. 
Previous studies show that metabolic 
disturbances associated with DCM often result 
in fibrosis and inflammation, and that these lead 
directly to contractile dysfunction (15). Ellmers 
et al. demonstrated that inhibition of PRR after 
myocardial infarction in mice ameliorates the 
cardiac fibrosis and impairment in cardiac 
dysfunction (16). Furthermore, inhibition of 
PRR attenuates mesangial cell proliferation and 
reduces the associated renal fibrosis (17). The 
present study has shown that PRR 
overexpression is associated with higher protein 
expression of fibronectin and profilin, whereas 
knockdown of PRR expression using RNA 
interference reduces the expression of collagen I 
and fibronectin in DCM rats. Collectively, this 
implies that PRR is involved in myocardial 
fibrosis in DCM. In addition, PRR knockdown 
inhibits cellular apoptosis in DCM. In addition, 
PRR overexpression and knockdown had 
complementary effects in high glucose-treated 
cardiac fibroblasts in vitro. Thus, the findings of 
the present and previous studies show that PRR 
is involved in determining the extent of 
myocardial injury in DCM. 
With regard to the inflammatory response, 
Kanda et al. recently reported that PRR RNA 
interference in rats alleviates the inflammation 
associated with diabetic retinopathy (18). The in 
vivo and in vitro findings of the present study 
are consistent with this, because PRR 
overexpression was found to aggravate the 
inflammatory response in DCM and to 
exacerbate the high glucose-induced 
inflammatory response in cardiac fibroblasts, 
whereas PRR silencing had the opposing effect, 
ameliorating some of the deleterious changes 
associated with DCM. Thus, PRR also seems to 
play a role in the regulation of the inflammatory 
response in DCM. 
The recent study by Rani et al. showed that 
during hyperglycemia there are changes to the 
redox status of cardiac cells, such that 
antioxidant therapy may be protective against 
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the effects of hyperglycemia (19). In addition, 
antioxidant therapy has been shown to alleviate 
inflammation and fibrosis, and thus to 
ameliorate the pathogenesis of cardiac 
complications in diabetic rats (20). Taken 
together, these findings imply that the 
exploitation of an antioxidant mechanism may 
be a viable therapeutic approach for DCM. In 
the present study, we found that PRR 
overexpression in DCM exacerbates oxidative 
stress, while PRR knockdown reduces oxidative 
stress in DCM rats. Our in vitro data also 
demonstrate that high glucose-induced ROS 
production is further up-regulated after PRR 
overexpression, while PRR knockdown has the 
opposite effect. Thus, the regulation of 
myocardial injury and the inflammatory 
response by PRR in DCM appear to be mediated 
through its antioxidant effects. 
It has been reported that PRR activation in 
mouse renal collecting duct cells increases 
fibrosis via MAPK-dependent ROS 
accumulation (21). We showed here that PRR 
overexpression increases ERK phosphorylation 
in a high-glucose environment, while PRR 
knockdown significantly ameliorates this effect. 
We then showed that the ERK inhibitor 
PD98059 prevents the PRR 
overexpression-induced activation of the ERK 
pathway, reducing ROS production, and 
inhibiting the changes involved in myocardial 
fibrosis and the inflammatory response in DCM. 
Thus, the effect of PRR on myocardial injury, 
the inflammatory response, and apoptosis is 
mainly associated with activation of the 
PRR/ERK/ROS pathway in DCM. 
In conclusion, PRR is an important component 
of the RAS and can regulate myocardial injury, 
the inflammatory response, and apoptosis in 
DCM. The underlying mechanism involves 
greater ROS production mediated through the 
ERK pathway. This implies that inhibition of 
PRR could represent a novel therapeutic 
approach for DCM, and that a beneficial effect 
would be dependent on inhibition of the 
PRR/ERK/ROS pathway. 
 
Experimental Procedures 
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PRR-expressing adenovirus construction 
The amplified open reading frame (ORF) of the 
PRR gene, which was designed by the 
GenePharma Company (Shanghai, China), was 
inserted into the pDC316 plasmid vector to 
construct pDC316-PRR. Then, the pDC316-PRR 
plasmid or pDC316-EGFP, as a control, and 
adenovirus vector were co-transformed into 
Escherichia coli to create recombinant 
adenoviruses expressing PRR (Ad-PRR) or 
EGFP (Ad-EGFP). 
 
PRR shRNA-expressing adenovirus 
construction 
Ad-PRR-shRNA was designed and constructed 
by the GenePharma Company (Shanghai, China) 
to achieve PRR RNA interference both in vivo 
and in vitro. The most efficient Ad-PRR-shRNA 
of three sequences was selected using western 
blot analysis (Ad-PRR-shRNA-547). The target 
sequence on the PRR gene was GCT CCG TAA 
TCG CCT GTT TCA. Adenovirus expressing 
scrambled shRNA (Ad-SC-shRNA) was also 
constructed as a control. 
 
Experimental animals 
Male Wistar rats (6–8 weeks, 200–250 g) were 
obtained from Shandong University Animal 
Centre and maintained in an animal room with 
controlled temperature (22°C ± 2°C) and 
humidity (55% ± 5%), under a 12 h light/dark 
cycle. 
The DCM model was established by a single 
intraperitoneal injection of streptozotocin (STZ) 
(65 mg/kg), and successful induction was 
accepted when blood glucose concentration 
was >11.1 mmol/L and there were compatible 
clinical signs. 
Rats were subjected to either PRR silencing or 
PRR overexpression. For the silencing 
experiment, the rats were randomly divided into 
four groups (n=15 per group): a control group, a 
DCM group, an Ad-SC-shRNA group, and an 
Ad-PRR-shRNA group. Twelve weeks after STZ 
administration, rats in the Ad-SC-shRNA, 
Ad-PRR-shRNA, and DCM groups were given 
an intravenous injection of recombinant 
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adenovirus expressing SC-shRNA (1×109 
plaque-forming units [pfu]), PRR-shRNA (1×109 
pfu) or PBS, respectively, via a tail vein. All the 
rats were maintained on a normal diet after the 
intravenous injection. Then, 2 weeks after the 
adenovirus injection, five rats per group were 
randomly selected to determine the degree of 
PRR silencing achieved, and the rest were 
maintained for a further 2 weeks, before further 
analyses were undertaken. 
For the PRR overexpression experiment, the rats 
were allocated to a DCM group, an Ad-PRR 
group, or an Ad-EGFP group. Twelve weeks 
after STZ administration, the rats in the DCM, 
Ad-PRR, and Ad-EGFP groups were given an 
intramyocardial injection of 1×109 pfu of 
Ad-PRR (in 200 µl of PBS), Ad-EGFP (in 200 
µl of PBS), or PBS only, respectively, in five 
separate locations of the left ventricular free 
wall, under anesthesia (10% chloral hydrate, 
300 mg/kg) and while being mechanically 
ventilated with a VIP Bird ventilator (tidal 
volume, 3.0 ml and respiratory rate, 60 
cycles/min; Bird Products Corp., Palm Springs, 
CA, USA). Two weeks after the Ad-PRR 
injection, four rats were randomly selected from 
each group for assessment of the efficiency of 
PRR overexpression, while the remaining 
animals were maintained for a further 2 weeks, 
before analyses were undertaken. During the 
study, one rat in the DCM group, one in the 
Ad-PRR-shRNA group, and two in the Ad-PRR 
group died. 
The animal procedures undertaken complied 
with the Guide for the Care and Use of 
Laboratory Animals from the National Academy 
of Sciences, published by the US National 
Institutes of Health (NIH Publication No. 86-23, 
revised 1996), and with the Principles of 
Laboratory Animal Care formulated by the 
National Society for Medical Research. The 
study was approved by the Institutional Animal 
Care and Use Committee of Shandong 
University  (Jinan, Shandong Province, China). 
 
Echocardiography measurements 
At the end of each animal study, the rats were 
anesthetized with 10% chloral hydrate (300 
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mg/kg, i.p.) for echocardiography using a 
Vevo770 imaging system (Visual Sonics, 
Toronto, Canada). M-mode signals, LVEF, the 
E/A ratio, LVEDD, and LVESD were measured. 
The values used represented the mean of five 
consecutive cardiac cycles. 
 
Immunohistochemistry 
Immunohistochemical staining was performed 
using the following steps. The paraffin sections 
were dewaxed and hydrated, then antigen 
retrieval was performed at >95°C using sodium 
citrate buffer, and non-specific reactions were 
blocked with goat serum for 15 min at 37°C. 
Then, the sections were incubated with primary 
polyclonal anti-PRR, anti-collagen I, 
anti-fibronectin, anti-profilin, anti-IL-1, or 
anti-IL-6 antibodies (Abcam, Cambridge, MA, 
USA) overnight at 4°C, all of which were diluted 
in 1× PBS to 1:200. Afterwards, the sections 
were incubated with a horseradish 
peroxidase-labeled secondary antibody (Abcam, 
Cambridge, MA, USA) for 20–30 min at 37°C. 
Negative control sections underwent the same 
treatment, but without addition of the primary 
antibody. The sections were then examined under 
a confocal FV 1000 SPD laser scanning 
microscope (Olympus Corporation, Tokyo, 
Japan). 
 
TUNEL assay 
Apoptotic cells in the hearts were detected using 
a TUNEL Assay Kit (In situ Direct DNA 
Fragmentation, Abcam, Cambridge, MA, USA). 
Images of the processed tissues were captured 
using fluorescence microscopy with 
excitation/emission wavelengths of 488/520 nm 
(Olympus, Japan). 
 
Western blot analysis 
Myocardial tissue and cell lysates were prepared, 
and the proteins were separated by SDS-PAGE 
and then transferred onto polyvinylidene 
difluoride membranes. Non-specific binding was 
minimized by incubation with 5% skim milk, 
then the membranes were incubated overnight at 
4°C with specific antibodies diluted 1:1000. The 
specific primary antibodies used were 
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anti-p-ERK, anti-t-ERK (Cell Signaling 
Technology, Danvers MA, USA), anti-(pro)renin 
receptor (Abcam, Cambridge, MA, USA), and 
GAPDH (Abcam, Cambridge, MA, USA), and 
horseradish peroxidase-conjugated secondary 
antibodies (Abcam, Cambridge, MA, USA) were 
used to detect specific antigen-antibody complex 
by ChemiDoc Touch Imaging System 
(Bio-RAD company, California, USA) . 
Densitometry was performed using Image J. 
 
Malondialdehyde assay 
The MDA content of the myocardium was 
measured using a commercially available kit 
based on thiobarbituric acid (TBA) reactivity 
(NanJing JianCheng Bioengineering Institute, 
China). Briefly, after fully mixing 0.1 ml of 
myocardial tissue homogenate with the reaction 
reagent, the mixture was heated at 95℃ for 40 
min and centrifuged at room temperature, and the 
supernatant was obtained and mixed with TBA. 
The T-MDA activity was measured at 532 nm 
using a spectrophotometer (Thermo Fisher 
Scientific, USA) and is expressed as units/mg of 
protein. 
Superoxide dismutase assay 
Myocardial tissue homogenate was also used to 
measure SOD activity by Superoxide Dismutase 
(SOD) assay kit (NanJing JianCheng 
Bioengineering Institute, China). When reacting 
with the chromogenic reagent, a purple color was 
produced at an intensity proportional to the 
nitrate content of the solution. The absorbance of 
each sample was quantified at 550 nm using the 
spectrophotometer, and T-SOD activity is 
expressed as units/mg of protein. 
 
NADPH oxidase activity 
NADPH oxidase activity was measured in 
myocardial tissue homogenates using a NADPH 
oxidase assay kit (Nan Jing Jian Cheng 
Bioengineering Institute, China). The absorption 
of the mixture was measured at 600 nm for 20 
and 80 s after the end of the reaction. 
 
Cell culture and treatments 
Cardiac fibroblasts were obtained from the 
myocardium of 1–3-day-old rats. Whole heart 
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was extracted and cut into the smallest pieces 
possible, then the myocardial matrix was 
digested using collagenase. The cell suspension 
was then cultivated for 1.5 h to distinguish 
cardiac fibroblasts from myocardial cells, 
according to their different growth rates. The 
supernatant was then discarded, and myocardial 
fibroblast culture medium was added. The cells 
were cultured in a humidified atmosphere of 5% 
CO2 and 95% air at 37°C until a typical growth 
pattern was observed. The culture medium 
consisted of endotoxin-free Dulbecco’s modified 
Eagle’s medium (DMEM; Thermo Fisher 
Scientific, USA) supplemented with 5.6 mM 
glucose and 10% fetal bovine serum (FBS; 
Thermo Fisher Scientific, USA). The cardiac 
fibroblasts were identified by the detection of 
vimentin expression, and second- to 
third-generation cardiac fibroblasts were 
transplanted into six-well plates for further 
experiments. The fibroblasts were used for 
either PRR silencing or overexpression. In 
addition, cells were either maintained in 5.6 mM 
glucose or switched to 25 mM glucose for 24 h 
to simulate the effects of hyperglycemia. 
 
Ad-shRNA infection in vitro 
Cells were cultivated in DMEM without FBS for 
more than 12 h, then infected with 
Ad-SC-shRNA or Ad-PRR-shRNA, or left 
uninfected. Adenovirus with an assured MOI of 
up to 150:1 was added to each well. After 12 h 
incubation in transfection reagent, the cells were 
then switched to normal medium for another 12 h, 
and then used for further experiments. 
 
Ad-PRR infection and treatment of cardiac 
fibroblasts in vitro 
The cells were cultivated in DMEM without FBS 
for more than 12 h, then infected with Ad-PRR or 
Ad-EGFP, or not infected. Adenovirus with an 
assured MOI of up to 150:1 was added to each 
well. After 12 h incubation in transfection 
reagent, the cells were then switched to normal 
medium for another 12 h, and then used for 
further experiments. Some cells were also 
pre-treated with the ERK inhibitor PD98059 (15 
µM, Selleck, Houston, TX, USA) in normal 
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glucose culture medium for 1 h, and then placed 
in medium containing 25 mM glucose ± ERK 
inhibitor (PD98059) for another 12 h. 
 
RNA extraction and real-time PCR 
Total RNA was isolated from myocardial tissues 
and cardiac fibroblasts using TRIzol Reagent 
(Thermo Fisher Scientific, USA). The purified 
RNA was diluted in diethylpyrocarbonate-treated 
water, and the concentration was determined. 
cDNA was synthesized from 1 mg of total RNA 
using a Prime Script 1st Strand cDNA Synthesis 
Kit (Takara, Japan). 
Gene expression was analyzed by real-time PCR 
using a Roche LightCycler 480 sequence 
detection system. PCR was performed in 20 µl 
reaction mixtures containing SYBR® Premix Ex 
Taq™ II using 40 amplification cycles. Each 
sample was analyzed in triplicate. The primers 
for rat IL-1, IL-6, collagen I, fibronectin, PRR, 
and GAPDH were purchased from the BioSune 
Company, and the cycling parameters used 
followed the manufacturer’s recommendations. 
The following primer sequences were used:  
PRR:  
Forward 5’-TCTGTTCTCAACTCGCTCCC-3’,  
Reverse 5’-TCTCCATAACGCTTCCCAAG-3’;  
IL-1β:  
Forward 
5’-GCCACCTTTTGACGTGATGAG-3’,  
Reverse  
5’-AGCTTCTCCACAGCCACAAT-3’;  
IL-6:  
Forward 
5’-CCCACCAGGAACGAAAGTCAA-3’,  
Reverse  
5’-CTGGAAGTCTCTTGCGGAG-3’;  
Collagen I:  
Forward 
5’-CACTGCAAGAACAGCGTAGC-3’,  
Reverse 
5’-AAGTTCCGGTGTGACTCGTG-3’;  
Fibronectin:  
Forward 
5’-ACAGCATCAGTGTCAGGTGG-3’,  
Reverse 5’-TAGGGCGGTCAATGTTGGTC-3’;  
GAPDH: 
Forward 5’-TCTCTGCTCCTCCCTGTTCT-3’,  
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Reverse 5’-ATCCGTTCACACCGACCTTC-3’. 
GAPDH was used as the reference gene. Relative 
quantification of the amplified cDNAs was 
achieved using a LightCycler 480 (Roche, 
Switzerland), and the target gene expression 
values were normalized to the expression of 
GAPDH mRNA. 
 
Measurement of ROS content 
ROS content was quantified using the 
oxidant-sensitive fluorescence probe DHE 
(Sigma-Aldrich, St. Louis, MO, USA). Cells 
were washed using serum-free medium three 
times and then incubated with DHE (5 µM) for 
30 min. Afterwards, images were captured at 
excitation/emission wavelengths of 535/610 nm. 
The fluorescence intensity was quantified using 
Imagine Plus Pro analysis software (Media 
Cybernetics Inc., MD, USA) in a blinded fashion. 
BLOG 
 
Enzyme-linked immunosorbent assay 
Cell supernatants were collected to determine the 
concentrations of collagen I, fibronectin, IL-1, 
and IL-6. All the concentrations were measured 
using kits, according to the manufacturer’s 
instructions (Abcam, Cambridge, MA, USA). 
Each experiment was conducted at least in 
triplicate. The optical density of each sample was 
determined at 450 nm using an Enzyme Standard 
Instrument (Thermo Fisher Scientific, USA) and 
used to calculate the concentration of each 
protein in the medium. 
 
Statistical analysis 
Statistical analyses were performed using SPSS 
19.0 software (IBM, Armonk, NY, USA). All 
data are expressed as the mean ± standard 
deviation of at least three independent 
experiments. The differences were analyzed 
using one-way ANOVA. After one-way 
ANOVA analysis, and least significant 
difference (LSD) were used to assess the 
statistical significance of the observed 
differences between groups. A statistically 
significant difference was considered to be 
present at P<0.05 
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Figure & Figure legends: 
  
  
Figure 1. The level of myocardial fibrosis, inflammation response and oxidative stress response 
in Ad-PRR group, Ad-EGFP group and DCM group: (A): Immunostaining of fibronectin, (B): 
Quantitative analysis of the results shown in (A). (C): Immunostaining of profilin. (D): 
Quantitative analysis of the results shown in (C). (E) Immunostaining of TNF-α. (F): 
Histograms (right) showing the quantitative analysis of the positive staining of (E). (G): 
Immunostaining of IL-6. (H): Quantitative analysis of the positive staining of (G).(I): SOD 
contents. (J): MDA contents. (K): NADPH oxidase activity in 3 groups; *P< 0.05 compared 
with the DCM group and Ad-EGFP group. Scale bar=20 μm, magnification 40×. 
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Figure 2. The levels of collagen I, fibronectin, IL-1, IL-6 protein expressions, TUNEL assay in 
3 groups. (A): Immunostaining of collagen I. (B) Quantitative analysis of the results shown in 
(A). (C): Immunostaining of fibronectin. (D): Quantitative analysis of the results shown in (C). 
(E): Representative images and analysis of the TUNEL assay. (F): Quantitative analysis of the 
results shown in (E). (G) Immunostaining of IL-1. (I): Histograms (right) showing the 
quantitative analysis of the positive staining of IL-1. (H): Immunostaining of IL-6. (J): 
Quantitative analysis of the positive staining of IL-6 in DCM group, Ad-SC-shRNA group, and 
Ad-PRR-shRNA group. *P< 0.05, **P<0.01 compared with the DCM group and 
Ad-SC-shRNA group. Scale bar=20 μm, magnification 40×. 
 
Figure 3. Oxidative stress response levels and cardiac function data in 3 groups of rats (A): 
SOD contents; (B): MDA contents; (C): NADPH oxidase activity; (D): Indicated left 
ventricular ejection fraction (LVEF); (E): Left ventricular end diastolic diameter (LVEDD); 
(F)Left ventricular end systolic dimension (LVESD) and (G): ratio of peak early to late 
diastolic filling velocity (E/A ratio) respective levels in the 3 groups in DCM group, 
Ad-SC-shRNA group, and Ad-PRR-shRNA group.  
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Figure 4. PRR protein, p-ERK, t-ERK protein expression and oxidative stress response level in 
cardiac fibroblasts in high glucose group, Ad-EGFP group, Ad-PRR group and 
Ad-PRR+PD98059 group. (A): Western blot showing PRR protein expression. (B): 
Quantitative analysis of the results shown in (A). (D): Western blot showing p-ERK, t-ERK 
protein expression. (C): Quantitative analysis of the results shown in (D). (E): DHE showing 
ROS production in 3 groups. (F) Quantitative analysis of the results shown in (E). *P< 0.05, 
**P<0.01 compared with the high glucose group and Ad-EGFP group; #P<0.05 compared with 
Ad-PRR group. Scale bar=50 μm, magnification 20× 
  
 
Figure 5. Collagen I, fibronectin, IL-1, IL-6 expression in high glucose group, Ad-EGFP group, 
Ad-PRR group and Ad-PRR+PD98059 group in vitro in cardiac fibroblasts. (A): Collagen I 
mRNA expression; (B): ELISA of collagen I protein expression. (C): fibronectin mRNA 
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expression; (D): ELISA of fibronectin protein expression. (E): IL-1 mRNA expression; (F): 
ELISA of IL-1 protein expression. (G): IL-6 mRNA expression; (H): ELISA of IL-6 protein 
expression. *P< 0.05 compared with the high glucose group and Ad-EGFP group; #P<0.05 
compared with Ad-PRR group. 
 
Figure 6. PRR protein, p-ERK, t-ERK protein expression; fibrosis, inflammation and oxidative 
stress response level in 3 groups’ cardiac fibroblasts (CFs). (A): Western blot showing PRR 
protein expression. (B): Quantitative analysis of the results shown in (A). (C): Western blot 
showing p-ERK, t-ERK protein expression. (D): Quantitative analysis of the results shown in 
(C).(E): DHE showing ROS production in 3 groups. (F) Quantitative analysis of the results 
shown in (E). (G-J): ELISA of collagen I, fibronectin, IL-1 and IL-6 protein expression in high 
glucose group, Ad-SC-shRNA group and Ad-PRR-shRNA group. *P< 0.05, **P<0.01 
compared with the high glucose group and Ad-SC-shRNA group. Scale bar=50 μm, 
magnification 20×. 
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